Drug Trial Radar · NCT06798454
Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)
Last checked: Nov 20, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Oct 15, 2024
Primary completion
Apr 23, 2025
Study completion Apr 23, 2025
Sponsor
- Lead sponsor
- Parvus Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Avance Clinical Pty Ltd.
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn what happens to PVT201 when it enters your body and how it affects your immune system. It will also learn about the safety of PVT201 after a single dose. The main questions it aims to answer are: Will participants experience any side effects when taking PVT201? How long does it take PVT201 to leave your body after you take it? Healthy volunteers will: stay in the clinic for two nights, get one dose of PVT201 or a placebo intravenously (through a vein) on Day 1, have blood drawn periodically throughout their stay and be monitored for side effects, and return to the clinic approximately one week after their dose for a final study visit. Patients with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC) will have the same procedures performed as healthy volunteers; however, none of the patients will receive placebo (all patients will be given PVT201).
Conditions
- Primary Biliary Cholangitis (PBC)
Interventions
PVT201Drug
Navacims are a novel class of nano-particle-based therapeutics being developed for the treatment of autoimmune diseases. A navacim consists of an iron oxide core surrounded by dextran that has been linked to multiple copies of a major histocompatibility complex Class II molecule and peptide. The peptide representing a disease-associated autoantigen and its paired MHC II molecule are specific to each autoimmune disease, and will be recognized by the T-cell antigen receptor. PVT201 is a navacim that will be used to target human PDC-reactive effector T-cells in patients with primary biliary cholangitis (PBC), converting them to Type 1 regulatory cells. IV delivery of navacims in nonclinical models of PBC induced immune tolerance and attenuation of disease pathology without impairing normal immunity to vaccines or viral and bacterial infections. PVT201 will be administered intravenously.
PlaceboOther
Participants randomized to placebo will be administered normal saline IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
- To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
- To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
- To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
- To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
- To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
- To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
- To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
- To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
- To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
- To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
- To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.